Abstract
Anticoagulant therapy is part of the treatment of hospitalized COVID-19 patients. Low molecular weight heparin or oral anticoagulant drugs are used in its treatment. However this approach may increase the risks of bleeding. Rectus sheath hematoma (RSH) is a known complication of anticoagulant therapy and a source of potential morbidity and mortality. Here; we present a patient who developed rectus hematoma during the COVID-19 treatment and followed by us with conservative approach.
Keywords: anticoagulation, COVID-19, rectus hematoma
Copyright and license
Copyright (c) 2021 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.
